Since the discovery of sclerostin in the 1990s as an inhibitor of canonical Wnt signaling and regulator of bone mass, a great deal of research has examined its therapeutic potential. This talk will give an overview of the development of sclerostin inhibitors, their application within the current armamentarium of osteoporosis therapies, and future opportunities raised by these agents.